Boston-based Beta Bionics, whose automated insulin dosing software the FDA approved in May 2023, raised a $100M Series D, taking its total funding to $293.5M (Andrea Park/Fierce Biotech)

Boston-based Beta Bionics, whose automated insulin dosing software the FDA approved in May 2023, raised a $100M Series D, taking its total funding to $293.5M (Andrea Park/Fierce Biotech)

Andrea Park / Fierce Biotech:
Boston-based Beta Bionics, whose automated insulin dosing software the FDA approved in May 2023, raised a $100M Series D, taking its total funding to $293.5M  —  In the wake of earning FDA clearance for its insulin pump an |  In the wake of earning FDA clearance for its insulin pump …